Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  MUMBAI STOCK EXCHANGE  >  Dr. Reddy's Laboratories Limited    500124   INE089A01023

DR. REDDY'S LABORATORIES LIMITED

(500124)
  Report
 SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Mumbai Stock Exchange
11/19/2020 11/20/2020 11/21/2020 11/23/2020 11/24/2020 Date
4707.3 4670.7 4670.7 4828.3 4910.95 Last
47362 31942 6 74602 45681 Volume
+0.09% -0.78% 0.00% +3.37% +1.71% Change
Financials
Sales 2021 193 B 2 607 M 2 607 M
Net income 2021 27 597 M 373 M 373 M
Net cash position 2021 10 068 M 136 M 136 M
P/E ratio 2021 29,6x
Yield 2021 0,52%
Sales 2022 216 B 2 921 M 2 921 M
Net income 2022 32 581 M 440 M 440 M
Net cash position 2022 29 623 M 400 M 400 M
P/E ratio 2022 25,1x
Yield 2022 0,58%
Capitalization 815 B 11 004 M 11 013 M
EV / Sales 2021 4,17x
EV / Sales 2022 3,63x
Nbr of Employees 21 650
Free-Float 68,2%
More Financials
Company
Dr. Reddy's Laboratories specializes in developing, producing, and selling pharmaceutical products. Net sales break down by activity as follows: - sales of generic medications (79.9%): brand-name or generic prescription medications and OTC medicines; - sales of active ingredients (15.7%). The group also supplies customized pharmaceutical services; - other (4.4%): sales of generic biopharmaceutical products,... 
Sector
Pharmaceuticals
Calendar
02/04Earnings Release
More about the company
Notations Surperformance© of Dr. Reddy's Laboratories Limited
Trading Rating : Investor Rating :
More Ratings
All news about DR. REDDY'S LABORATORIES LIMITED
11/20DR REDDY LABORATORIES : Half yearly disclosure of related party transactions - S..
PU
11/17India pins hopes on locally-tested COVID-19 vaccines given Pfizer constraints
RE
11/16APPILI THERAPEUTICS : Reports Financial and Operational Results for Second Quart..
AQ
11/12DR REDDY LABORATORIES : Announces the Launch of Succinylcholine Chloride Injecti..
BU
11/12India's Serum says made 40 million doses of AstraZeneca's COVID vaccine, to m..
RE
11/09DR REDDY LABORATORIES : Presents Preclinical Data at SITC 2020 Demonstrating Sig..
BU
10/29DR REDDY LABORATORIES : Outcome of Board Meeting
PU
10/29DR REDDY LABORATORIES : . Reddy's partners with Department of Biotechnology - Bi..
BU
10/28DR REDDY LABORATORIES : India trials of Russian Sputnik-V vaccine may end as ear..
RE
10/28DR REDDY LABORATORIES : . Reddy's Names Parag Agarwal Chief Financial Officer
DJ
10/28DR REDDY LABORATORIES : Announces Appointment of New Chief Financial Officer
BU
10/28DOCTOR REDDY'S : Fiscal 2Q Earnings Snapshot
AQ
10/28DR REDDY LABORATORIES : . Reddy's Q2 & H1 FY21 Financial Results
BU
10/28DR REDDY LABORATORIES : 2Q Net Fell 30%
DJ
10/22Dr Reddy's isolates data center services after cyberattack
RE
More news
News in other languages on DR. REDDY'S LABORATORIES LIMITED
05/15DR. REDDY'S LABORATORIES LIMITED : Veröffentlichung des Jahresergebnisses
05/15DR. REDDY'S LABORATORIES LIMITED : publication des résultats annuels
05/08DR. REDDY'S LABORATORIES LIMITED : Veröffentlichung des Jahresergebnisses
05/08DR. REDDY'S LABORATORIES LIMITED : publication des résultats annuels
2019INDIVIOR : paie cher sa dépendance au Subutex
More news
Chart DR. REDDY'S LABORATORIES LIMITED
Duration : Period :
Dr. Reddy's Laboratories Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends DR. REDDY'S LABORATORIES LIMITED
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 33
Average target price 5 522,33 INR
Last Close Price 4 910,95 INR
Spread / Highest target 30,3%
Spread / Average Target 12,4%
Spread / Lowest Target -18,5%
EPS Revisions
Managers
NameTitle
Erez Israeli Chief Executive & Operating Officer
Saumen Chakraborty President, CFO & Global Head-IT
Satish Kallam Reddy Co-Chairman
Gunupati Venkateswara Prasad Co-Chairman & Managing Director
Kalpana Jaisingh Morparia Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
DR. REDDY'S LABORATORIES LIMITED70.69%11 004
JOHNSON & JOHNSON-1.37%378 744
ROCHE HOLDING AG-3.77%283 004
MERCK & CO., INC.-11.73%203 111
PFIZER INC.-6.59%202 993
NOVARTIS AG-13.38%198 168